Intersect ENT (NSDQ:XENT) this morning posted wider-than-expected losses but topped the consensus sales estimate with its third-quarter results. Menlo Park, Calif.-based Intersect reported losses of -$12.8 million, or -41¢ per share, on sales of $24.1 million for the three months ended Sept. 30. Get the full story at our sister site, Drug Delivery Business News
Intersect ENT’s Ascend study misses endpoint
Intersect ENT (NSDQ:XENT) shares plunged today after the company said it failed to meet the primary endpoint in a study of its Ascend investigational drug-coated sinus balloon. The 70-person, randomized, double-blind trial was designed to compared treatment with Intersect ENT’s DCB when randomized against an uncoated balloon control. The study missed the primary endpoint, frontal sinus […]
FDA approves delivery system for Intersect ENT’s Propel implant
Intersect ENT (NSDQ:XENT) said today that it won FDA approval for a new delivery system for its Propel Mini steroid-eluting sinus implant. The Menlo Park, Calif.-based company said the straight delivery system is designed to place the mometasone furoate-eluting Propel Mini in the ethmoid sinus behind the nasal bridge. The SDS is slated to hit […]
Intersect ENT lures Hologic’s West for CEO | Personnel Moves, June 28, 2019
Intersect ENT (NSDQ:XENT) yesterday named Hologic (NSDQ:HOLX) executive Tom West to be its new president & CEO effective July 22. West, who has been president of Hologic’s diagnostics solutions division since October 2014, is a Johnson & Johnson (NYSE:JNJ) veteran, Menlo Park, Calif.-based Intersect ENT said. The company in May tapped lead director Kieran Gallahue to […]
Wright Medical creates digital arm, promotes Asper to chief digital officer | Personnel Moves – May 7, 2019
Wright Medical (NSDQ:WMGI) said today that it is creating a new digital division and that it is promoting strategy, tech & corporate dev senior VP Jason Asper to chief digital officer. The new CDO title comes alongside Asper’s existing responsibilities, Amsterdam-based Wright Medical said. The new digital division will focus on the company’s digital surgery strategy […]
Intersect ENT posts mixed-bag Q1 earnings
Intersect ENT (NSDQ:XENT) today posted first quarter earnings that topped sales expectations but missed loss-per-share consensus on Wall Street. The Menlo Park, Calif.-based company posted losses of $10.8 million, or 35¢ per share, on sales of $26.7 million for the three months ended March 31, seeing losses grow 76.1% while sales grew 7.9% compared with the […]
Intersect ENT wins preliminary CMS reimbursement code
Shares in Intersect ENT (NSDQ:XENT) got a boost yesterday on news that the Centers for Medicare and Medicaid Services (CMS) had assigned the company’s Sinuva corticosteroid-eluting sinus implant a preliminary J-code. Intersect ENT stock, which had been bumping along just under $30 per share last week, jumped to $33.13 per share at Monday’s market open, then […]
Intersect ENT shares dip despite street-beating Q4, 2018 earnings
Shares in Intersect ENT (NSDQ:XENT) have fallen slightly today despite the medical device maker released fourth quarter and full year 2018 earnings that met consensus expectations from analysts on Wall Street. The Menlo Park, Calif.-based company posted losses of $5 million, or 16¢ per share, on sales of approximately $32.8 million for the three months ended […]
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. Get the full story at our sister site, Drug […]
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon. The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation. Get the full story at our sister site, Drug Delivery Business News.
Intersect ENT touts pooled analysis of steroid-releasing sinus implants
Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining. Get the full story at our […]
- 1
- 2
- 3
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube